GLP-1s, which have been used for years to treat type 2 diabetes, have gained widespread attention as a way to lose weight and reduce obesity-related conditions and their long-term costs
Drug manufacturer Novo Nordisk produces it under the brand name Rybelsus, and the FDA approved it for managing blood glucose in people with Type 2 diabetes but not Type 1 diabetes
Even if people can afford the drugs, shortages have plagued patients
Each time, the adaptation period tends to be slightly shorter and slightly less intense than the previous one, because the GLP-1 receptors are increasingly accustomed to agonist activity
For instance, some individuals think they will stop taking them once theyve lost weight while others are only using them cosmetically and not for management of a chronic disease. Call for more research In a new JAMA Viewpoint opinion piece, Khan and others call for more research to understand the causes of this discontinuation and the development of clinical and policy interventions to support long-term use
[DOI] [PubMed] [Google Scholar] 6.Mechanisms of action and therapeutic application of glucagon-like peptide-1
%25201.png)
